AUA/SUFU Validate Peripheral Tibial Nerve Stimulation (PTNS) For The Treatment Of Overactive Bladder In Newly Published Guidelines - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
AUA/SUFU Validate Peripheral Tibial Nerve Stimulation (PTNS) For The Treatment Of Overactive Bladder In Newly Published Guidelines


AUA/SUFU Validate Peripheral Tibial Nerve Stimulation (PTNS) For The Treatment Of Overactive Bladder In Newly Published Guidelines

PR Newswire

MINNEAPOLIS, June 30, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, reported that in the recently updated Overactive Bladder (OAB) treatment guideline from the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), Percutaneous Tibial Nerve Stimulation (PTNS) is listed as a recommended third-line therapy. Uroplasty's Urgent® PC is the only commercially available PTNS system.

"The classification of PTNS as a recommended therapy demonstrates the urology community's acceptance of Urgent PC based on strong clinical evidence," said Rob Kill, President and Chief Executive Officer of Uroplasty. "It reinforces the fact that PTNS should be offered to refractory OAB patients because the benefit of PTNS outweighs any burden or risk associated with treatment." 

The updated AUA guideline was prompted by a review of clinical data published since 2012, when the AUA/SUFU OAB guideline was first introduced. The updated guideline incorporates 11 new PTNS publications that include outcomes from nine studies, including a European randomized control trial against placebo and long-term data from the Sustained Therapeutic Effects of Percutaneous tibial nerve stimulation (STEP) study.

"This is some of our most compelling data and demonstrates Urgent PC's long-term results and performance compared to sham," said Mr. Kill. "The AUA / SUFU guideline underscores Urgent PC's role as a therapy for the millions of OAB patients who do not achieve success with behavioral modifications or medications.  Urgent PC is an ideal, low-risk option for OAB patients affected by this debilitating disease who do not want to undergo an invasive or higher-risk procedure."  

About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 42 million US adults.  The symptoms include urinary urgency, frequency and urge incontinence.  The Urgent PC Neuromodulation System is the only commercially available FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only commercially available, FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults.  The symptoms include urinary urgency, frequency and urge incontinence.  We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952.426.6152

EVC Group
Doug Sherk (Investors)/Janine McCargo (Business Media)
415.652.9100/646.688.0245

SOURCE Uroplasty, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here